

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

DUSA PHARMACEUTICALS INC

Form 8-K

April 15, 2004

FORM 8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 14, 2004

DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

NEW JERSEY (State or other jurisdiction of incorporation)	0-19777 (Commission File Number)	22-3103129 (IRS Employer Identification Number)
--------------------------------------------------------------------	--------------------------------------------	--------------------------------------------------------------

25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)

(978) 657-7500
(Registrant's telephone number, including area code)

ITEM 5. OTHER EVENTS.

On April 14, 2004, DUSA Pharmaceuticals, Inc. ("DUSA") announced that Levulan(R) Kerastick(R) end-user sales to physicians increased in its first quarter 2004. DUSA also announced an increase in BLU-U(R) units placed in doctors' offices and that it participated in the 2004 annual meeting of the American Society of Laser Medicine and Surgery in Dallas, Texas.

ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.

[99] Press Release dated April 14, 2004.

Edgar Filing: DUSA PHARMACEUTICALS INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DUSA PHARMACEUTICALS, INC.

Dated: April 14, 2004

By: /s/ D. Geoffrey Shulman

D. Geoffrey Shulman, MD, FRCPC
President and Chief Executive
Officer